Search
Rutin
go.drugbank.com/drugs/DB01698ApprovedInvestigationalA flavonol glycoside found in many plants, including buckwheat; tobacco; forsythia; hydrangea; viola, etc. It has been used therapeutically to decrease capillary fragility.
Synonyms: Vitamin PCategories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersDuvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalDuvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative a...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesEntrectinib
go.drugbank.com/drugs/DB11986ApprovedInvestigationalEntrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesAvatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigationalAvatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby
Categories: Thrombopoietin Receptor Agonist, P-glycoprotein substratesFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalFostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP . Fostamatinib has...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigational[A179209] Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigationalThe World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980. However, there have been longstanding concerns that smallpox may be used as a bioweapon. Tecovirimat is an antivira...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP3A InducersLetermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives ca...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesLandiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigationalLandiolol is a rapid-acting beta (β)-1 adrenergic receptor blocker that blocks the positive chronotropic effect of the beta-1 selective agonist norepinephrine.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsSiponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigational[L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates